Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15305872 | 0.91 | TP53 (0.37) | HDAC4TP53MAPTSMN1; SMN2GAA | |
| SCHEMBL21767203 | 0.85 | TP53 (0.41) | TP53SMN1; SMN2POLBGAAKMT2A | |
| SCHEMBL25492206 | 0.77 | GAA (0.46) | TP53SMN1; SMN2GAAKMT2APKM | |
| SCHEMBL15308244 | 0.77 | TUBB4A (0.46) | TP53MAPTTDP1GAAKMT2A | |
| SCHEMBL8736025 | 0.77 | TP53 (0.52) | TP53MAPTSMN1; SMN2GAAKMT2A | |
| SCHEMBL8734890 | 0.76 | PKM (0.46) | TP53TDP1GAAKMT2ALMNA | |
| SCHEMBL25492204 | 0.67 | GAA (0.49) | TP53SMN1; SMN2GAAPKM | |
| SCHEMBL25492200 | 0.67 | TUBB4A (0.48) | TP53MAPTTDP1GAAKMT2A | |
| SCHEMBL25492175 | 0.65 | GAA (0.47) | TP53MAPTSMN1; SMN2GAAKMT2A | |
| SCHEMBL25492286 | 0.63 | PKM (0.52) | TP53TDP1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061072-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2020-02-27 | — | — | US | disclosed |
| US-10220040-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2019-03-05 | — | — | US | disclosed |
| US-20180064718-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | ABIONYX PHARMA (FR) | 2018-03-08 | — | — | US | disclosed |
| US-9757381-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-09-12 | — | — | US | disclosed |
| US-9757381-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-09-12 | — | — | US | disclosed |
| US-9713619-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160361318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20160361318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20150344455-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-12-03 | — | — | US | disclosed |
| US-9085585-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-07-21 | — | — | US | disclosed |
| US-20130267554-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-10-10 | — | — | US | disclosed |
| US-8349833-B2 | Compounds, compositions and methods useful for cholesterol mobilisation | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-01-08 | — | — | US | disclosed |
| US-8349833-B2 | Compounds, compositions and methods useful for cholesterol mobilisation | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-01-08 | — | — | US | disclosed |
| US-20120129856-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | CERENIS THERAPEUTICS SA (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120129856-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | CERENIS THERAPEUTICS SA (FR) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064718-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | HDAC4 560/4885TP53 4671/4885MAPT 2213/4885 |
| US-10220040-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CETP, LIPA, NPC1L1 | HDAC4 560/4885TP53 4671/4885MAPT 2213/4885 |
| US-20120129856-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | CETP, NPC1L1, NPC1 | HDAC4 1402/4885TP53 4091/4885MAPT 1542/4885 |
| US-20150344455-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | HDAC4 560/4885TP53 4671/4885MAPT 2213/4885 |
| US-20130267554-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | HDAC4 560/4885TP53 4671/4885MAPT 2213/4885 |
| US-20200061072-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | HDAC4 560/4885TP53 4671/4885MAPT 2213/4885 |
| US-20160361318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | HDAC4 560/4885TP53 4671/4885MAPT 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.